Table 2.

Risk factors for proven or probable IA among case (n = 187) and control (n = 1495) patients who received allogeneic HSCTs at FHCRC, 1993-1998

Controls, no. (%)Cases, no. (%)HR95% CI
Recipient-related factors
 Age, y
  Younger than 19239 (16.0)23 (12.3)1.0
  19-40634 (42.4)67 (35.8)1.5NS
  Older than 40622 (41.6)97 (51.9)2.41.5-3.82-153
 Underlying disease
  CML, chronic phase367 (24.6)37 (19.8)1.0
  Hematologic malignancy, first remission151 (10.1)15 (8.0)1.1NS
  Hematologic malignancy, other650 (43.5)79 (42.3)1.61.1-2.42-155
  Other* 327 (21.9)56 (30.0)2.11.4-3.22-153
Transplant-related factors (donor and stem cell source)
 MR BM509 (34.1)57 (30.5)1.0
 MR PBSCs175 (11.7)17 (9.1)0.7NS
 MM/UR BM779 (52.1)103 (55.1)1.1NS
 MM/UR PBSCs22 (1.5)7 (3.7)2.81.1-7.02-155
 Cord blood10 (0.7)3 (1.6)5.11.5-17.22-155
 T cell–depleted/CD34-selected54 (3.6)16 (8.6)2.21.2-4.12-155
Transplant complications
 Neutropenia 3.02.0-4.62-153
 GVHD, acute,
  Grades 0-11.0
  Grades 2-42.21.4-3.42-153
  Missing2.1NS
 GVHD, chronic (clinically extensive), 2.21.3-3.72-155
 CMV disease 7.04.5-10.82-153
 Respiratory virus infection 2.11.4-3.12-153
  • Hazard ratios (HRs) and 95% confidence intervals (CIs) are shown for all significant variables.

  • —indicates data not applicable; NS, not significant in the multivariable model.

  • * The most common “other” diagnoses are aplastic anemia, myelodysplastic syndrome, and multiple myeloma.

  • Factors entered into the model as time-dependent covariates.

  • The GVHD variable “missing” signifies patients who did not have data entered into the computerized system (n = 118). Acute and chronic GVHD were independently graded, as previously described.17 18

  • F2-153 P ≤ .001.

  • F2-155 P ≤ .05.